Ignite Creation Date:
2024-05-06 @ 4:25 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04979988
Status:
COMPLETED
Last Update Posted:
2024-04-05
First Post:
2021-07-19
Brief Title:
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
Sponsor:
Pfizer
Organization:
Pfizer